Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas-Reference-Cited by-同舟云学术

Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas

Published:2015-11-30 Issue:2 Volume:18 Page:173-183
ISSN:1522-8517
Container-title:Neuro-Oncology
language:en
Short-container-title:Neuro Oncol

Author:

Baumgarten Peter,Blank Anna-Eva,Franz Kea,Hattingen Elke,Dunst Maika,Zeiner Pia,Hoffmann Katharina,Bähr Oliver,Mäder Lisa,Goeppert Benjamin,Machein Marcia,Seifert Volker,Steinbach Joachim P.,Plate Karl H.,Harter Patrick N.,Mittelbronn Michel

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Neurology (clinical),Oncology

Link

http://academic.oup.com/neuro-oncology/article-pdf/18/2/173/7640720/nov288.pdf

Reference48 articles.

1. The 2007 WHO Classification of Tumours of the Central Nervous System

2. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

3. Tumor Angiogenesis: Therapeutic Implications

4. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo;Kim;Nature,1993

5. Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Silico Approach to Model Heat Distribution of Magnetic Hyperthermia in the Tumoral and Healthy Vascular Network Using Tumor-on-a-Chip to Evaluate Effective Therapy;Pharmaceutics;2024-08-31

2. Unlocking Hope: Anti-VEGFR inhibitors and their potential in glioblastoma treatment;Critical Reviews in Oncology/Hematology;2024-06

3. The safety and efficacy of bevacizumab in treatment of recurrent low-grade glioma: a systematic review and meta-analysis;European Journal of Clinical Pharmacology;2024-05-11

4. The role of angiogenic growth factors in the immune microenvironment of glioma;Frontiers in Oncology;2023-09-13

5. Phase II Randomized Trial of Lenalidomide in Children With Pilocytic Astrocytomas and Optic Pathway Gliomas: A Report From the Children's Oncology Group;Journal of Clinical Oncology;2023-06-20